Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)

• CCR East •
• 1 May, 2026 •
• •

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

• CCR East •
• 1 May, 2026 •
• •

Efficacy and Safety of Emapalumab in Patients with Macrophage Activation Syndrome (MAS) in Systemic Lupus Erythematosus (SLE)

Alexei A. Grom, Shoghik Akoghlanian, Melissa Elder, Renee Modica, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

• CCR East •
• 1 May, 2026 •
• •

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullman, Adnan Mahmood, Andrew Danquah, Elena Burillo, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

• AMCP Nexus •
• 28 October, 2025 •
• •

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients With Still’s Disease (Systemic Juvenile Idiopathic Arthritis [sJIA] and Adult-onset Still’s Disease [AOSD]): Analysis of a US National Administrative Claims Database

Michael Marrone, Christopher McPherson, Abiola Oladapo

Available materials